Mentor Capital, Inc. Acquires 20% of Cutting Edge Cancer Immunotherapy Company: Quantum Immunologics, Inc.

Fri. July 10, 2009; Posted: 05:28 PM

Look up the PowerRating of MNTR and see how it has performed over the past week as well as the current proprietary PowerRating.

SAN DIEGO, Jul 10, 2009 (BUSINESS WIRE) -- MNTR | Quote | Chart | News | PowerRating -- Mentor Capital, Inc. (Pink Sheets: MNTR | Quote | Chart | News | PowerRating) is pleased to announce that it is providing equity funding to support Quantum Immunologics, Inc. (QI) to complete their FDA authorized Phase I/II trials on metastatic breast cancer, which are now underway (NCT00879489). QI holds exclusive license to patents that pertain to certain therapeutic and diagnostic applications of the Oncofetal Antigen (OFA), a universal marker found on all tested cancer lines but not found in normal tissues. The current QI clinical approach is to externally process and sensitize dendritic cells from the patient's own blood to recognize the OFA in their breast cancers as a marker for diseased tissue. The sensitized dendritic cells are then re-injected into the patient to stimulate their body's own immune system to attack the cancerous cells in an effort to eradicate or stabilize the patient's disease. Dendreon (DNDN) utilizes a similar dendritic immunotherapy approach, but focuses on a prostate-specific protein, through its Provenge product.

In addition to providing $2.2 Million in funding to help support the FDA trials through approximately February 2010, Mentor Capital has agreed to assist QI in funding future strategic stock or cash acquisitions. Mentor will also stand by as a preferred funding source for QI during later stage or additional trials. In exchange for this financial support, Mentor Capital has received common stock in QI reflecting a carried interest of 20%. At the current private placement price for the QI shares, the acquisition of the QI position increases Mentor Capital assets per share by $3.74 per share.

The Oncofetal Antigen - Immature Laminin Receptor patents are a product of 20 years and $30 Million of research at The University of South Alabama Medical & Science Foundation and were primarily funded by the National Institute of Health's National Cancer Institute. The complete Quantum Immunologics corporate story, including a summarizing video of the QI breast cancer treatment methodology that is entering FDA trials, may be found at their company web site: www.QuantumImmunologics.com. Comprehensive information on Mentor Capital, including capital structure detail, can be found at: www.MentorCapital.com. Level II quotes, news, financial information and trading charts may be referenced at www.PinkSheets.com under the trading symbol MNTR.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

SOURCE: Mentor Capital, Inc.

Mentor Capital, Inc. 
Chet Billingsley, CEO 
760-788-4700

For full details for MNTR click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.